P. Plas

发表

Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment

T. Leanderson, Anders Olsson, J. Nakhlé, 2015, Journal of Immunotherapy for Cancer.

Down-regulation of atrial natriuretic factor receptors and correlation with cGMP stimulation in rat cultured vascular smooth muscle cells.

P. Braquet, P. Plas, P. Chabrier, 1987, Biochemical and biophysical research communications.

Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion.

F. Roudot-thoraval, C. Brun-Buisson, P. Braquet, 1989, The Journal of clinical investigation.

Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response.

K. Clément, A. Basdevant, P. Plas, 2010, The Journal of endocrinology.

Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity.

P. Plas, M. Contour-Galcéra, C. Thurieau, 2001, Journal of medicinal chemistry.

Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice

M. Culler, A. Butler, Hyunwon Yang, 2009, Peptides.

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [177Lu]Lu-OPS201 Compared to the Agonist [177Lu]Lu-DOTA-TATE

G. Vauquelin, P. Plas, R. Mansi, 2021, Pharmaceuticals.

Receptor regulation of atrial natriuretic factor.

P. Braquet, P. Plas, P. Chabrier, 1990, Blood vessels.

Regulation of atrial natriuretic factor receptors by angiotensin II in rat vascular smooth muscle cells.

P. Braquet, P. Plas, P. Chabrier, 1988, The Journal of biological chemistry.

3-Thio-1,2,4-triazoles, novel somatostatin sst2/sst5 agonists.

P. Plas, M. Contour-Galcéra, A. Sidhu, 2005, Bioorganic & medicinal chemistry letters.

Decrease in endothelin-1 renal receptors during the 1st month of life in the rat

M. Déchaux, P. Plas, M. Charbit, 1996, Pediatric Nephrology.

Preparation and Infusion of Cryoprecipitate from Exercised Donors

J. Sixma, P. Plas, B. Bouma, 1973, British journal of haematology.

Blood-brain barrier and atrial natriuretic factor.

P. Braquet, P. Plas, P. Chabrier, 1988, Canadian journal of physiology and pharmacology.

Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer

J. Nakhlé, P. Plas, A. Bauchet, 2016, Oncoimmunology.

Endothelin receptor regulation by endothelin synthesis in vascular smooth muscle cells: effects of dexamethasone and phosphoramidon.

P. Braquet, P. Plas, J. Schulz, 1993, Journal of vascular research.

Angiotensin II and phorbol-esters potently down-regulate endothelin (ET-1) binding sites in vascular smooth muscle cells.

P. Braquet, P. Plas, J. Guillon, 1989, Biochemical and biophysical research communications.

Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment

Lisa U. Magnusson, Anders Olsson, P. Plas, 2016, The Prostate.

Identification of a novel series of benzimidazoles as potent and selective antagonists of the human melanocortin-4 receptor.

P. Plas, P. Roubert, L. Poitout, 2007, Bioorganic & medicinal chemistry letters.

Endothelin receptor subtypes A and B are up-regulated in an experimental model of acute renal failure.

P. Braquet, P. Plas, P. Chabrier, 1994, Molecular pharmacology.

Upregulation of renal endothelin receptors in glycerol-induced acute renal failure in the rat.

P. Braquet, P. Plas, P. Chabrier, 1993, Journal of cardiovascular pharmacology.

Binding characteristics of endothelin isoforms (ET-1, ET-2, and ET-3) in vascular smooth muscle cells.

P. Braquet, P. Plas, P. Chabrier, 1991, Journal of cardiovascular pharmacology.

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours

P. Plas, S. Lezmi, O. Raguin, 2022, Pharmaceuticals.